Arkolith/Insider Trading/PCSA/Form 4

Young David

Pres. Research & Development, DirectorProcessa Pharmaceuticals, Inc. (PCSA) · full profile →Form 4 · filed Aug 2, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
8
4 non-derivative · 4 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jul 10, 2024Tax withholding(F)282$1.71$48281K
Jul 10, 2024Option exercise(M)644——81K
Apr 5, 2024Tax withholding(F)518$2.79$1K81K
Apr 5, 2024Option exercise(M)2K——81K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 28, 2024Grant(A)2K—$024K
Jun 28, 2024Grant(A)404—$025K
Jun 28, 2024Grant(A)404—$025K
Jun 28, 2024Grant(A)3K—$022K

Transaction Codes

F
Shares withheld for taxes
M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000897069-24-001606) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML